
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Calyx has announced that Catalyst Clinical Research is entering into a partnership with Calyx to use Calyx’s Medical Imaging solution for their customers’ oncology trials.
The ACTIVATE Solutions for CRO Partners program is designed to provide alignment between Calyx and its CRO partners. By participating in the ACTIVATE CRO program, Catalyst aims to better meet the imaging needs of their clients and help accelerate oncology trial execution and data collection.
For more information, click






